Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS

被引：0

作者：

Crusoe, Edvan De Queiroz ^{[1
,2
,3
]}

Leal, Joanna ^{[4
]}

Santos, Juliana Andrade ^{[5
,6
]}

de Melo Santos, Herbert Henrique ^{[7
]}

Santos, Allan de Souza ^{[7
]}

Lucas, Larissa Ferreira ^{[6
]}

Almeida, Alessandro de M. ^{[8
,9
]}

Chaves, Marcos ^{[10
]}

Dutra, Daniela Dourado ^{[5
]}

Hungria, Vania T. M. ^{[11
,12
]}

Salvino, Marco Aurelio ^{[2
,13
]}

Arruda, Maria da Gloria B. ^{[6
]}

机构：

[1] Univ Fed Bahia Hosp Univ, Rua Dra Doutro Vianna S-n, Salvador, BA, Brazil

[2] Hosp Univ Prof Edgard Santos Fed Univ Bahia HUPES, Salvador, BA, Brazil

[3] Clin CEHON Rede Dor Oncol, Hematol Dept Dor Oncol, Salvador, BA, Brazil

[4] Hematol Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[5] Univ Fed Bahia, Salvador, BA, Brazil

[6] CLin CEHON Rede Dor Oncol, Hematol, Salvador, BA, Brazil

[7] Univ Fed Bahia, Immunol Mol & Cytometry Lab ICS, Salvador, BA, Brazil

[8] Univ Fed Bahia, Stem Cell Transplant Unit, Salvador, BA, Brazil

[9] Rede Dor Oncol, Hematol & Bone Marrow Unit, Salvador, BA, Brazil

[10] Fed Univ Bahia Hematol & Hemotheraphy, Salvador, BA, Brazil

[11] Santa Casa Med Sch, Hematol, Sao Paulo, Brazil

[12] Clin Sao Germano, Dept Hematol & Oncol, Sao Paulo, Brazil

[13] Rede Dor Oncol, Hematol & Bone Marrow Transplantat UNIT, Salvador, BA, Brazil

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-164866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7699 / 7700

页数：2

共 50 条

[31] Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.
Touzeau, Cyrille
Moreau, Philippe
Perrot, Aurore
Hulin, Cyrille
Dib, Mamoun
Tiab, Mourad
Caillot, Denis
Facon, Thierry
Leleu, Xavier
van de Donk, Niels W. C. J.
Broijl, Annemiek
Zweegman, Sonja
Levin, Mark-David
Delforge, Michel
Pei, Lixia
Vanquickelberghe, Veronique
De Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis
Dimopoulos, Meletios
Sonneveld, Pieter
Rodriguez-Otero, Paula
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels
Katodritou, Eirini
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Moreau, Philippe
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S30 - S31
[33] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
Sonneveld, Pieter
Dejoie, Thomas
Zweegman, Sonja
Merz, Maximilian
Weisel, Katja
Lam, Annette
Krotneva, Stanimira
Proskorovsky, Irina
Kampfenkel, Tobias
de Boer, Carla
Cote, Sarah
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E201 - E202
[34] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
Hungria, Vania T. M.
Moura, Fernanda Lemos
Soares, Paulo
Lima, Juliana Souza
Ricci, Lisa Aquaroni
Nucci, Fabio Moore
Oliveira Ribeiro, Eduardo Flavio
Crusoe, Edvan de Queiroz
Lima, Marinus de Moraes
Pessoa de Magalhaes Filho, Roberto Jose
Arrais-Rodrigues, Celso
Bhaumik, Amitabha
Parekh, Trilok
Borgsten, Fredrik
Carson, Robin
Trufelli, Damila C.
Costa, Abel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
[35] Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.
Moreau, Philippe
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Superiority of Triple Combination Bortezomib plus Cyclophosphamide and Dexamethasone (VCD) Versus Thalidomide plus Cyclophosphamide and Dexamethasone (CTD) in Newly Diagnosed Multiple Myeloma Transplant-Eligible Patients
Crusoe, Edvan De Queiroz
Higashi, Fabiana
Martinez, Gracia
Bittencourt, Rosane
Maiolino, Angelo
Sousa, Lais
Nunes, Renata Ferreira Marques
Ribeiro, Glaciano
Nicacio, Jandir
Zanella, Karla Richter
Magalhaes, Andre
Leao, Danielle
Pinto Neto, Jorge Vaz
Hallack Neto, Abrahao Elias
Braga, Walter
Souza, Emmanuella G.
Guimaraes, Antonio Julio A. M.
Durigon, Giovanna Steffenello
Laks, Dani
Kutner, Jose Mauro
Colli, Gilberto
Santucci, Rodrigo
Magalhaes, Roberto Jose Pessoa
Hungria, Vania T. M.
BLOOD, 2017, 130
[37] Daratumumab (Dara) Versus Isatuximab (Isa): Perceptions of AntiCluster of Differentiation 38 (CD38) Monoclonal Antibody (mAb) Use in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM)
Moffett, Nicholas
Bone, Robert N.
Jeune-Smith, Yolaine
Baljevic, Muhamed
Feinberg, Bruce
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S563 - S563
[38] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[39] Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China
Fu, Chengcheng
Wang, Jing
Yan, Lingzhi
Jin, Song
Shang, Jingjing
Shi, Xiaolan
Yao, Weiqin
Yan, Zhi
Wu, De-Pei
BLOOD, 2023, 142
[40] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)

← 1 2 3 4 5 →